Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer
Authors
Keywords
Apparent Diffusion Coefficient, Trastuzumab, Metastatic Breast Cancer, Nodular Regenerative Hyperplasia, Portal Venous Pressure
Journal
Targeted Oncology
Volume 12, Issue 2, Pages 229-234
Publisher
Springer Nature
Online
2017-01-21
DOI
10.1007/s11523-017-0477-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine
- (2016) Jeremy Force et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?
- (2014) D. K. Woolf et al. ANNALS OF ONCOLOGY
- Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety Analysis
- (2014) Véronique Diéras et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapy monitoring of skeletal metastases with whole-body diffusion MRI
- (2014) Anwar R. Padhani et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
- Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2013) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessing the Relation Between Bone Marrow Signal Intensity and Apparent Diffusion Coefficient in Diffusion-Weighted MRI
- (2012) Anwar R. Padhani et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism
- (2012) Ben-Quan Shen et al. CURRENT DRUG METABOLISM
- A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
- (2012) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prostate cancer: localizing the cancer in patients with persistent negative biopsies
- (2012) H.-P. Schlemmer CANCER IMAGING
- Diffusion Magnetic Resonance Imaging in Cancer Patient Management
- (2011) Anwar R. Padhani SEMINARS IN RADIATION ONCOLOGY
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules
- (2010) M. Lopus et al. MOLECULAR CANCER THERAPEUTICS
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now